Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study following JRM-001 treatment in pediatric patients with congenital heart disease
jRCT2060260051Recruiting
- Sponsor
- Metcela Inc.
- Start
- Aug 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of deramiocel in Cardiovascular Malformation (CVM) (2 arms), sponsored by Metcela Inc. Primary endpoint: Adverse events or serious adverse events up to 12 months of this study. Started Aug 2026; status: recruiting.
02
Drugs
deramiocel
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on jRCT2060260051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2060260051.